Tempus to buy Personalis for $1.5B, betting on cancer-monitoring market
What's the deal? Tempus AI has agreed to acquire Personalis in a transaction valuing the molecular diagnostics company at a $1.5 billion enterprise value, net of Tempus' existing stake. Personalis shareholders will receive $16.25 per share, a 6% premium to Friday's closing price and a 28% premium to the unaffected 30-day volume-weighted average price.
What each side brings: Tempus, listed on the Nasdaq, uses AI to support precision oncology through its multimodal data platform. Personalis makes tumor-informed minimal residual disease (MRD) tests, including NeXT Personal, which detects small traces of circulating tumor DNA to track treatment response and flag cancer recurrence early.
Why now? The two firms have partnered since November 2023, when Tempus invested in Personalis and commercialized the NeXT Personal test. Chris Hall, chief executive officer of Personalis, said that after "an exhaustive process," the company was confident Tempus' offer provided "the most value to our shareholders."
What's the endgame? The acquisition extends Tempus across the cancer care continuum — from diagnosis and treatment selection through recurrence and long-term monitoring. Roughly 2.1 million new cancer diagnoses are expected in the US this year, with more patients living longer after diagnosis and needing ongoing monitoring.
The market: Tempus values the emerging MRD market at $20 billion. NeXT Personal already has Medicare coverage in three indications, with more anticipated, giving the combined company reimbursement momentum as clinical adoption grows.
The terms: The deal is structured as a 100% stock transaction, though Tempus can elect to pay in cash at its discretion, capped at 50% of the consideration.
The signal: "MRD is a large and rapidly growing market with the potential to truly transform how cancer patients are monitored," said Eric LefkofskyDealroom has a profile for this one. Try Dealroom →, chief executive officer of Tempus. The deal reflects a broader consolidation of diagnostics and AI in oncology, as companies race to own more of the patient journey and the data it generates.
Read more: Business Wire
